
Anne Lanceley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1985328/publications.pdf Version: 2024-02-01



ANNE LANCELEY

#	Article	IF	CITATIONS
1	Improving the effectiveness of multidisciplinary team meetings for patients with chronic diseases: a prospective observational study. Health Services and Delivery Research, 2014, 2, 1-172.	1.4	212
2	Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health, 2017, 17, 503.	2.9	195
3	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncology, The, 2013, 14, 236-243.	10.7	125
4	International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12). Journal of the National Cancer Institute, 2017, 109, .	6.3	115
5	Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). European Journal of Cancer, 2011, 47, 183-190.	2.8	91
6	Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials. Journal of the National Cancer Institute, 2019, 111, 1170-1178.	6.3	76
7	Use of controlling language in the rehabilitation of the elderly. Journal of Advanced Nursing, 1985, 10, 125-135.	3.3	65
8	Development of an EORTC quality of life phase III module measuring cancerâ€related fatigue (EORTC) Tj ETQq0 (0 0 rgBT /0 2.9	Overlock 10 Tf
9	Determinants of treatment plan implementation in multidisciplinary team meetings for patients with chronic diseases: a mixed-methods study. BMJ Quality and Safety, 2014, 23, 867-876.	3.7	51
10	Obesity, Diet, Physical Activity, and Health-Related Quality of Life in Endometrial Cancer Survivors. Nutrition Reviews, 2015, 73, 399-408.	5.8	49
11	Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast, 2015, 24, 237-241.	2.2	48
12	Mainstreamed genetic testing for women with ovarian cancer: first-year experience. Journal of Medical Genetics, 2019, 56, 195-198.	3.2	48
13	Heritage, health and well-being: assessing the impact of a heritage focused intervention on health and well-being. International Journal of Heritage Studies, 2013, 19, 229-242.	1.9	44

14	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 2018, 27, 59-74.	3.1	40	
15	Attitudes, challenges and needs about diet and physical activity in endometrial cancer survivors: a qualitative study. European Journal of Cancer Care, 2017, 26, e12531.	1.5	37	
16	Phase 1–3 of the crossâ€cultural development of an <scp>EORTC</scp> questionnaire for the assessment of sexual health in cancer patients: the <scp>EORTC SHQ</scp> â€22. Cancer Medicine, 2018, 7, 635-645.	2.8	37	
17	Using Museum Objects to Improve Wellbeing in Mental Health Service Users and Neurological Rehabilitation Clients. British Journal of Occupational Therapy, 2013, 76, 208-216.	0.9	26	
10	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) –		2.6	

18Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 2018,1.426148, 36-41.

ANNE LANCELEY

#	Article	IF	CITATIONS
19	Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial. BMJ Open, 2017, 7, e018015.	1.9	25
20	Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. International Journal of Art Therapy: Inscape, 2012, 17, 63-79.	1.6	23
21	Family History and Women With Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 254-259.	2.5	23
22	Enhancing Cancer Patient Well-Being With a Nonpharmacological, Heritage-Focused Intervention. Journal of Pain and Symptom Management, 2012, 44, 731-740.	1.2	21
23	Inviting end-of-life talk in initial CALM therapy sessions: A conversation analytic study. Patient Education and Counseling, 2017, 100, 259-266.	2.2	21
24	Investigating the therapeutic potential of a heritage-object focused intervention: a qualitative study. Journal of Health Psychology, 2012, 17, 809-820.	2.3	20
25	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study. Oncologist, 2017, 22, 1117-1124.	3.7	20
26	Use of intervention mapping to adapt a health behavior change intervention for endometrial cancer survivors: the shape-up following cancer treatment program. BMC Public Health, 2018, 18, 415.	2.9	19
27	Sensitivity to change of the EORTC quality of life module measuring cancerâ€related fatigue (EORTC) Tj ETQq1	1 0,78431	4 rgBT /Overla
28	Consent in pregnancy: A qualitative study of the views and experiences of women and their healthcare professionals. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 238, 132-137.	1.1	19
29	Diet, physical activity, and health-related outcomes of endometrial cancer survivors in a behavioral lifestyle program: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomized controlled pilot trial. International Journal of Gynecological Cancer, 2019, 29, 531-540.	2.5	19
30	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	3.7	19
31	Evaluating the therapeutic effects of museum object handling with hospital patients: A review and initial trial of well-being measures. Journal of Applied Arts and Health, 2011, 2, 37-56.	0.4	18
32	Generic well-being outcomes: towards a conceptual framework for well-being outcomes in museums. Museum Management and Curatorship, 2011, 26, 237-259.	1.4	17
33	Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: study protocol for a randomized controlled trial. Trials, 2016, 17, 130.	1.6	16
34	Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK. BMJ Open, 2017, 7, e017675.	1.9	16
35	Let's be PALS: User-Driven Organizational Change in Healthcare*. British Journal of Management, 2005, 16, 315-328.	5.0	15
36	Cancer in Other Words? The Role of Metaphor in Emotion Disclosure in Cancer Patients. British Journal of Psychotherapy, 2013, 29, 182-201.	0.2	15

ANNE LANCELEY

#	Article	IF	CITATIONS
37	Use of a formal consensus development technique to produce recommendations for improving the effectiveness of adult mental health multidisciplinary team meetings. BMC Psychiatry, 2015, 15, 143.	2.6	15
38	Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. BMJ Open, 2016, 6, e012863.	1.9	15
39	Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey. BMC Women's Health, 2017, 17, 132.	2.0	15
40	Mentalization in CALM psychotherapy sessions: Helping patients engage with alternative perspectives at the end of life. Patient Education and Counseling, 2019, 102, 188-197.	2.2	15
41	Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). European Journal of Cancer, 2021, 154, 235-245.	2.8	15
42	Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. International Journal of Gynecological Cancer, 2022, 32, 761-768.	2.5	15
43	Consent in pregnancy - an observational study of ante-natal care in the context of Montgomery: all about risk?. BMC Pregnancy and Childbirth, 2021, 21, 102.	2.4	14
44	Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. International Journal of Gynecological Cancer, 2020, 30, 221-226.	2.5	13
45	Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk. Familial Cancer, 2015, 14, 135-144.	1.9	11
46	International perspectives on suboptimal patientâ€reported outcome trial design and reporting in cancer clinical trials: A qualitative study. Cancer Medicine, 2021, 10, 5475-5487.	2.8	11
47	Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. BMC Public Health, 2017, 17, 882.	2.9	10
48	Consent on the labour ward: A qualitative study of the views and experiences of healthcare professionals. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 264, 150-154.	1.1	9
49	Quality criteria for patient advice and liaison services: what do patients and the public want?. Health Expectations, 2005, 8, 126-137.	2.6	8
50	The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients. Anthropology and Medicine, 2020, 27, 449-464.	1.2	8
51	Choice in episiotomy – fact or fantasy: a qualitative study of women's experiences of the consent process. BMC Pregnancy and Childbirth, 2022, 22, 139.	2.4	8
52	Patient Advice and Liaison Services: strengthening the voices of individual service users in health-care organizations. Health Expectations, 2006, 9, 138-147.	2.6	7
53	Patient experience of MDT care and decision-making. Mental Health Review Journal, 2014, 19, 265-278.	0.7	6
54	Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol. BMJ Open, 2018, 8, e017282.	1.9	6

Anne Lanceley

#	Article	IF	CITATIONS
55	The Assessment of Mentalization: Measures for the Patient, the Therapist and the Interaction. Journal of Contemporary Psychotherapy, 2020, 50, 57-65.	1.2	6
56	Wider issues in pain management. European Journal of Cancer Care, 1995, 4, 153-157.	1.5	5
57	Moving towards populationâ€based genetic risk prediction for ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 855-858.	2.3	5
58	Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecologic Oncology, 2022, 166, 254-262.	1.4	5
59	Attitudes towards a programme of risk assessment and stratified management for ovarian cancer: a focus group study of UK South Asians' perspectives. BMJ Open, 2018, 8, e021782.	1.9	4
60	Patient-centred consent in women's health: does it really work in antenatal and intra-partum care?. BMC Pregnancy and Childbirth, 2022, 22, 156.	2.4	4
61	The early lives and times of London PALS. British Journal of Health Care Management, 2003, 9, 18-20.	0.2	3
62	Cancer patient satisfaction with health care professional communication: An international EORTC study. Psycho-Oncology, 2022, 31, 541-547.	2.3	3
63	Therapeutic Values in Cancer Care. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2022, 41, 121-128.	1.2	3
64	Horizontal or Vertical Support: Dilemmas for Patient Advice and Liaison Services in the NHS. Public Policy and Administration, 2005, 20, 54-66.	2.0	1
65	Differences in health care professionals' and cancer patients' views on sexual health issues. Psycho-Oncology, 2018, 27, 2299-2302.	2.3	1
66	Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS) Journal of Clinical Oncology, 2016, 34, 5508-5508.	1.6	1
67	Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS) Journal of Clinical Oncology, 2017, 35, 5575-5575.	1.6	1
68	Can GPs and PALS be friends?. British Journal of General Practice, 2003, 53, 818-9.	1.4	1
69	Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) Journal of Clinical Oncology, 2015, 33, 5564-5564.	1.6	0
70	Stepped approach to improving sexual function after gynaecological cancer: the SAFFRON feasibility RCT. Health Technology Assessment, 2019, 23, 1-92.	2.8	0
71	How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC) Journal of Clinical Oncology, 2019, 37, 5549-5549.	1.6	0
72	Toward Personalized Informed Consent in Cancer Care. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2022, 41, 210-214.	1.2	0

#	Article	IF	CITATIONS
73	Association of adult attachment with delays in accessing specialist care in women with ovarian cancer. Journal of Psychosocial Oncology, 2022, 40, 491-505.	1.2	0